I am not an expert at all in this but I guess that
Post# of 36536
(Total Views: 333)
Posted On: 08/17/2021 12:41:16 PM
I am not an expert at all in this but I guess that NGIO is really in a quiet period following the S1 filing. So, maybe they can’t talk about the IND submission?
This S1 has been filed almost 3 months ago and generally the SEC reviews it and provides comments under 30 days. Then the companies responds to the comments and amends the S1 form. Finally, the S1 become effective. Nothing happened for NGIO in 3 months, it is hard to guess what’s going on.
I just hope that the IND will be accepted soon so that they can receive some money from Bintai, submit an IND in China and start the trials. It is the most important from my point of view. I don’t know what can go wrong with the IND knowing that they were just waiting the stability tests, but we are always surprised... If they can’t get an IND, I guess that they would not have any credibility for the IPO.
Otherwise, there is maybe nothing significant to say about RPM or Excellagen. Hopefully, they are progressing in the fill and finish and start getting some sales. From my quick searches, Excellagen was approved 10 years ago and is not a really successful drug... but there were some sales in late 2019 (?) which raises some hopes.
It is just my thoughts about the current situation, I am not as experienced as you guys.
This S1 has been filed almost 3 months ago and generally the SEC reviews it and provides comments under 30 days. Then the companies responds to the comments and amends the S1 form. Finally, the S1 become effective. Nothing happened for NGIO in 3 months, it is hard to guess what’s going on.
I just hope that the IND will be accepted soon so that they can receive some money from Bintai, submit an IND in China and start the trials. It is the most important from my point of view. I don’t know what can go wrong with the IND knowing that they were just waiting the stability tests, but we are always surprised... If they can’t get an IND, I guess that they would not have any credibility for the IPO.
Otherwise, there is maybe nothing significant to say about RPM or Excellagen. Hopefully, they are progressing in the fill and finish and start getting some sales. From my quick searches, Excellagen was approved 10 years ago and is not a really successful drug... but there were some sales in late 2019 (?) which raises some hopes.
It is just my thoughts about the current situation, I am not as experienced as you guys.
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼